Insiders selling shares, particularly below current price, may be a negative signal. Yet, the level of insider ownership suggests some alignment between management and smaller shareholders. The absence of insider transactions in the last three months doesn't offer much insight into the company's current situation.
Artisan Partners' P/E ratio hints at investor optimism despite earnings drop, but analysts see less promise. The gap between P/E ratio and negative earnings growth may impact future stock performance.
Despite EPS growth and decent TSR due to dividends, APAM's less impressive share price growth indicates a pessimistic market perception. Be aware of 1 warning sign.
Tiffany Hsiao, fund manager of$Artisan Partners Asset Management(APAM.US)$, an American boutique investment institution, said that the market is large and growing, which is the most attractive point. Specifically, at the company level, Tiffany Hsiao introduced that she values companies committed to solving major problems and meeting unmet needs. For these companies, once consumers want to buy again, their brands are their trus...
$Artisan Partners Asset Management(APAM.US)$I bought this in the low 40s after a avoiding it for years do to thinking it will crash with a market crash. I no longer care . It will come back and the div is a great cushion. Rare is the company with virtually no debt and great ROIC and I locked in a 9% dividend. I will add more on big dips and some on small ones. This company manages their clients differently and is worldwide. I think they have a sticky customer base. I will add more when I can lo...
Artisan Partners Asset Management股票討論區
Specifically, at the company level, Tiffany Hsiao introduced that she values companies committed to solving major problems and meeting unmet needs. For these companies, once consumers want to buy again, their brands are their trus...
• $Actinium(ATNM.US)$ +30.81% (Actinum Pharma and Immedica to commercialize lomab-B (1311 apamistamab) in Europe the Middle East and North Africa)
• $Aeglea BioTherapeutics(AGLE.US)$ +18.11% (presents additional data from PEACE phase 3 study of Pegzilarginase; submits BLA to FDA for Pegzilarginase)
• $Grid Dynamics(GDYN.US)$ +5% (expands in Europe ceases operations in Russia)
• $Artisan Partners Asset Management(APAM.US)$ +4....
暫無評論